Cormorant Asset Management
Cormorant Asset Management reported 50 stocks worth $2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (11.0%), BBOT (7.0%) and PBLS (6.5%). Compared with Q1 2026, the fund opened new positions in PBLS, CLYM and SYRE, added to ERAS, ANL and BHVN, trimmed PRAX, RAPP and EWTX and sold out of MAZE, ASND and ZURA.
Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 |  PRAX Praxis Precision Medicines I | $214M | 11.0% | 640K | −246K (−28%) | 8 of 8 | |
| 2 |  BBOT Bridgebio Oncology Therapeut | $136M | 7.0% | 17.9M | No change | 4 of 8 | |
| 3 |  PBLS Parabilis Medicines Inc Com | $126M | 6.5% | 4.6M | New position | 1 of 8 | |
| 4 |  RAPP Rapport Therapeutics Inc | $111M | 5.7% | 2.7M | −300K (−10%) | 8 of 8 | |
| 5 |  ERAS Erasca Inc | $110M | 5.6% | 6M | +200K (+3%) | 2 of 8 | |
| 6 |  EWTX Edgewise Therapeutics Inc | $102M | 5.2% | 2.5M | −750K (−23%) | 8 of 8 | |
| 7 |  EYPT Eyepoint Pharmaceuticals Inc | $100M | 5.1% | 7M | −1.3M (−15%) | 8 of 8 | |
| 8 |  ALMS Alumis Inc | $92.5M | 4.7% | 3.3M | −664K (−17%) | 8 of 8 | |
| 9 |  ABVX Abivax SA | $90M | 4.6% | 675K | −85K (−11%) | 8 of 8 | |
| 10 |  DNTH Dianthus Therapeutics Inc | $73.1M | 3.8% | 750K | −200K (−21%) | 2 of 8 |
Positions at Jun 30, 2026, as reported. Change is against the fund's Q1 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q1 2026, gone in Q2 2026| Stock | Value last quarter | Shares sold |
|---|---|---|
CENTESSA PHARMACEUTICALS PLC | $41.7M | 1.1M |
 MAZE Maze Therapeutics Inc | $22.4M | 750K |
 ASND Ascendis Pharma A/s | $21.7M | 95K |
TERNS PHARMACEUTICALS INC | $15.8M | 300K |
 ZURA Zura Bio Ltd | $8.6M | 1.4M |
🔒 Free account: see all 9.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q2 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Aug 14, 2026 | 13F-HR | Q2 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Cormorant Asset Management 13F FAQ
What does Cormorant Asset Management own?
Cormorant Asset Management reported 50 stocks worth $2B in its 13F filing for Q2 2026, filed Aug 14, 2026. Its largest holdings are PRAX (11.0%), BBOT (7.0%) and PBLS (6.5%). The table above lists every position in the filing (the top 10 without an account).
What did Cormorant Asset Management buy and sell in Q2 2026?
Compared with Q1 2026: 13 new positions, 4 added to, 28 trimmed and 9 sold out. New positions include PBLS, CLYM and SYRE. It sold all of MAZE, ASND and ZURA.
When will Cormorant Asset Management file its next 13F?
Holdings as of Sep 30, 2026 are due by Nov 16, 2026. The filing appears on this page within minutes of reaching the SEC.
How much is Cormorant Asset Management's portfolio worth?
The Q2 2026 filing reports $2B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.